Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Erasca, Inc. - Common Stock
(NQ:
ERAS
)
15.72
+0.77 (+5.15%)
Streaming Delayed Price
Updated: 3:53 PM EDT, Jun 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Erasca, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800%
↗
May 29, 2026
This clinical-stage biotech develops targeted oral therapies for RAS/MAPK-driven cancers, with all assets currently in development.
Via
The Motley Fool
Topics
Regulatory Compliance
Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally
↗
May 18, 2026
This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway cancers, advancing a pipeline of novel oncology candidates.
Via
The Motley Fool
Topics
Regulatory Compliance
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter
↗
May 17, 2026
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors.
Via
The Motley Fool
Topics
Regulatory Compliance
Erasca (NASDAQ:ERAS) Beats Q1 Estimates on Promising ERAS-0015 Data
↗
May 11, 2026
Via
Chartmill
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally
↗
May 17, 2026
This clinical-stage biotech develops antibody therapies for severe autoimmune diseases, targeting rare neuromuscular conditions.
Via
The Motley Fool
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More
↗
May 17, 2026
This clinical-stage biotech targets RAS/MAPK pathway cancers with a pipeline of novel small molecule oncology therapies.
Via
The Motley Fool
Topics
Regulatory Compliance
Erasca Touts 'Eye-Popping' ERAS-0015 Lung Cancer Data, FDA Path at BofA Conference
↗
May 16, 2026
Erasca (NASDAQ:ERAS) executives said the company sees multiple potential development paths for its RAS-targeting portfolio, highlighting early clinical activity for ERAS-0015 in lung, pancreatic and...
Via
MarketBeat
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy
↗
May 16, 2026
This San Diego biotech develops targeted therapies for RAS/MAPK-driven cancers, advancing several clinical candidates in oncology.
Via
The Motley Fool
Topics
Regulatory Compliance
What to Know About This Fund’s $50 Million Exit From Ascendis Pharma
↗
May 14, 2026
Ascendis Pharma develops long-acting therapies for rare endocrine and pediatric diseases using its proprietary TransCon technology.
Via
The Motley Fool
Topics
Regulatory Compliance
This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO
↗
May 14, 2026
Veradermics develops novel dermatology treatments, targeting both adult and pediatric markets with a research-driven approach.
Via
The Motley Fool
Topics
Initial Public Offering
Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700%
↗
May 14, 2026
This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway-driven cancers, addressing hard-to-treat tumor types.
Via
The Motley Fool
Topics
Regulatory Compliance
Stock Market Today, April 28: Erasca Plunges After Patient Death in Early Cancer Drug Trial
↗
April 28, 2026
Today, April 28, 2026, investors are weighing how a trial death will reshape Erasca's investment thesis.
Via
The Motley Fool
Topics
Stocks
Here are the top movers in Tuesday's session.
↗
April 28, 2026
Via
Chartmill
Which stocks are experiencing notable movement on Tuesday?
↗
April 28, 2026
Via
Chartmill
Gapping stocks in Tuesday's session
↗
April 28, 2026
Via
Chartmill
Top movers in Tuesday's pre-market session
↗
April 28, 2026
Via
Chartmill
What's going on in today's after hours session
↗
April 27, 2026
Via
Chartmill
Erasca CMO's Direct Stake Hit Zero. Her Options Position Didn't
↗
March 26, 2026
This oncology biotech, developing targeted cancer therapies, reported a notable insider sale following a remarkable year for its stock.
Via
The Motley Fool
Topics
Regulatory Compliance
Erasca (ERAS) Stock Slides After The Bell: Here's Why
↗
January 20, 2026
Erasca Inc (NASDAQ:ERAS) shares are moving lower in extended trading Tuesday after the company announced a proposed public offering.
Via
Benzinga
Erasca Insider Sells $671K as Stock Jumps 189% This Past Year
↗
January 13, 2026
This oncology biotech developing targeted cancer therapies saw a key insider significantly trim their direct equity stake.
Via
The Motley Fool
Topics
Regulatory Compliance
Get insights into the top gainers and losers of Thursday's after-hours session.
↗
January 08, 2026
Via
Chartmill
The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader
January 08, 2026
The first week of 2026 has set the biotech sector ablaze, with Revolution Medicines (NASDAQ: RVMD) finding itself at the epicenter of a high-stakes acquisition tug-of-war. Shares of the Redwood...
Via
MarketMinute
Topics
Intellectual Property
Get insights into the top gainers and losers of Thursday's pre-market session.
↗
January 08, 2026
Via
Chartmill
Stay updated with the stocks that are on the move in today's after-hours session.
↗
January 07, 2026
Via
Chartmill
Fidus Investment, Rocket Companies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
↗
October 02, 2025
Via
Benzinga
Why Concorde International Group Shares Are Trading Higher By 55%; Here Are 20 Stocks Moving Premarket
↗
October 02, 2025
Via
Benzinga
This Accenture Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
↗
September 03, 2025
Via
Benzinga
Erasca Narrows Loss 46% in Fiscal Q2
↗
August 12, 2025
Via
The Motley Fool
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday
↗
April 21, 2025
Via
Benzinga
This Spotify Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
↗
March 26, 2025
Via
Benzinga
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
